Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic TransplantationAbraham S. Kanate, Mehdi Hamadani, Parameswaran Hari et al.|Transplantation and Cellular Therapy|2017Cited by 11
Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantationAbraham S. Kanate, Mehdi Hamadani, Aaron Cumpston et al.|Hematology/Oncology and Stem Cell Therapy|2011Cited by 10
93: Outcome with a thiotepa containing regimen and autologous HSCT in patients with NHLAaron Cumpston, Solveig G. Ericson, Deirdre Bulian et al.|Transplantation and Cellular Therapy|2007Cited by 1
Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT)Mehdi Hamadani, Abraham S. Kanate, Marcelo C. Pasquini et al.|Transplantation and Cellular Therapy|2016Cited by 1
Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell TransplantationSalman Osman, Sayed Mehdi Hamadani, Abraham S. Kanate et al.|Blood|2010Cited by 0